BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20533438)

  • 1. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
    Christensen JD; Colby TV; Patz EF
    Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer.
    Takenaka T; Yano T; Ito K; Morodomi Y; Miura N; Kawano D; Shoji F; Abe K; Honda H; Maehara Y
    J Surg Oncol; 2009 Dec; 100(8):688-92. PubMed ID: 19731260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
    Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
    Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; Dupont PJ; De Leyn PR; Verbeken EK; Deneffe GJ; Mortelmans LA; Demedts MG
    J Clin Oncol; 1999 Oct; 17(10):3201-6. PubMed ID: 10506619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
    Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
    Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
    J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
    Hong R; Halama J; Bova D; Sethi A; Emami B
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
    Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N
    Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
    Bahce I; Vos CG; Dickhoff C; Hartemink KJ; Dahele M; Smit EF; Boellaard R; Hoekstra OS; Thunnissen E
    Lung Cancer; 2014 Aug; 85(2):205-12. PubMed ID: 24854401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
    Yu J; Li X; Xing L; Mu D; Fu Z; Sun X; Sun X; Yang G; Zhang B; Sun X; Ling CC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1468-74. PubMed ID: 19464822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Glut-1 glucose transporter expression with.
    Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
    Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
    Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
    J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
    Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
    Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.